COMPANY RESEARCH PROFILE · UPDATED 2026-09-29

Innovent Biologics

China's leading PD-1 innovator. Sintilimab (Tyvyt) is one of China's top-selling PD-1 inhibitors, developed in partnership with Eli Lilly for global rights. Expanding into metabolic disease with mazdutide (GLP-1/glucagon dual agonist) competing in the obesity space. HKEX-listed only (1801.HK).

TICKER1801.HK

HEADQUARTERSSuzhou, China

STAGEApproved

ACTIVE TRIALS67

Therapeutic areas

OncologyImmunologyMetabolicCardiovascular

Selected products and programs

SintilimabBevacizumab BiosimilarMazdutideIBI362

Linked curated drug profiles

No curated drug entity is linked in the current pilot.

Selected active clinical trials

Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity

Phase 3 · Recruiting · Overweight

A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease

Phase 3 · Recruiting · Thyroid Eye Disease

A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

Phase 3 · Recruiting · Sleep Apnea

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)

Phase 3 · Recruiting · Pancreatic Cancer

A Study of IBI362 in Chinese Adolescents With Obesity or Overweight

Phase 3 · Recruiting · Adolescents With Obesity or Overweight With Weight-Related Comorbidities

IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

Phase 3 · Recruiting · Colorectal Cancer

Selected patent records

No linked FDA Orange Book patent record was found for the selected products.

Primary and company sources

en.innoventbio.com ↗

Company and pipeline information can change. Verify material decisions against the linked primary sources.

Evidence & limits

Source: Open the source record

Record identifier: /companies/innovent-biologics/
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.

Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.

Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.

What this record means · Report an issue with this record